Organisme Type de programme
  • Subvention
    There is currently one FDA-approved drug for the treatment of Amyotrophic Lateral Sclerosis (ALS), riluzole (Rilutek), improving survival by two to three months. Other treatments are available that relieve the symptoms associated with ALS and improve the quality of life for patients living with the disease by providing comfort to the patient. However, there is an urgent need for improved therapies. With the recent progress in understanding ALS, the increased effort to develop tools to identify novel treatments for the disease and advances in technology, the opportunity to discover improved treatments for ALS could not be better. The ALS Association’s TREAT ALS™ program funds research from early target identification to preclinical research and early pilot clinical trials. As part of the program, The Association is requesting letters of intent for its drug development contract program, milestone driven research to develop new treatments for ALS. The program compliments the Department of Defense ALS research program and the translational programs at the National Institutes of Health.(2015-03)
Personne-ressource au Vice-rectorat à la recherche et à la création Domaine(s) concerné(s) Adresse(s) Internet : Fiche numéro : 2546
Dernière mise à jour : 10 mars 2015

Demande de correction   Demande de correction